How to turn elegant VLP concepts into stable, GMP-minded products for intranasal, oral, and other mucosal routes Virus-like particles (VLPs) are a natural fit for mucosal vaccines: their repetitive, ordered architectures can focus immune responses where soluble antigens often fall short. However, the execution gap isn’t the concept—it’s translating design choices such as epitope density, […]